WO2024081960A2 - Procédés de conservation et de protection de cardiomyocytes et de réduction de la fibrose cardiaque à la suite d'une lésion cardiaque - Google Patents
Procédés de conservation et de protection de cardiomyocytes et de réduction de la fibrose cardiaque à la suite d'une lésion cardiaque Download PDFInfo
- Publication number
- WO2024081960A2 WO2024081960A2 PCT/US2023/077001 US2023077001W WO2024081960A2 WO 2024081960 A2 WO2024081960 A2 WO 2024081960A2 US 2023077001 W US2023077001 W US 2023077001W WO 2024081960 A2 WO2024081960 A2 WO 2024081960A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pkm2
- composition
- mutant
- pyruvate kinase
- cardiac
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 81
- 210000004413 cardiac myocyte Anatomy 0.000 title claims description 92
- 208000013875 Heart injury Diseases 0.000 title claims description 23
- 230000009787 cardiac fibrosis Effects 0.000 title claims description 19
- 102000013009 Pyruvate Kinase Human genes 0.000 claims abstract description 82
- 108020005115 Pyruvate Kinase Proteins 0.000 claims abstract description 82
- 239000000203 mixture Substances 0.000 claims abstract description 80
- 208000010125 myocardial infarction Diseases 0.000 claims abstract description 69
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 41
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 39
- 230000001154 acute effect Effects 0.000 claims abstract description 11
- 210000004165 myocardium Anatomy 0.000 claims description 29
- 239000000539 dimer Substances 0.000 claims description 26
- 241000282414 Homo sapiens Species 0.000 claims description 19
- 230000034994 death Effects 0.000 claims description 14
- 230000035772 mutation Effects 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 6
- 238000004321 preservation Methods 0.000 claims description 4
- 230000007423 decrease Effects 0.000 claims description 3
- 210000001723 extracellular space Anatomy 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 2
- 206010061216 Infarction Diseases 0.000 abstract description 36
- 238000011282 treatment Methods 0.000 abstract description 25
- 230000000694 effects Effects 0.000 abstract description 24
- 230000007574 infarction Effects 0.000 abstract description 21
- 206010000891 acute myocardial infarction Diseases 0.000 abstract description 7
- 241000699670 Mus sp. Species 0.000 description 41
- 235000001014 amino acid Nutrition 0.000 description 38
- 235000018102 proteins Nutrition 0.000 description 37
- 229940024606 amino acid Drugs 0.000 description 36
- 150000001413 amino acids Chemical class 0.000 description 35
- 150000007523 nucleic acids Chemical group 0.000 description 30
- 230000001225 therapeutic effect Effects 0.000 description 30
- 210000001519 tissue Anatomy 0.000 description 30
- 108090000765 processed proteins & peptides Proteins 0.000 description 26
- 102000004196 processed proteins & peptides Human genes 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 24
- 102000039446 nucleic acids Human genes 0.000 description 24
- 108020004707 nucleic acids Proteins 0.000 description 24
- 229920001184 polypeptide Polymers 0.000 description 24
- 206010021143 Hypoxia Diseases 0.000 description 22
- 125000003275 alpha amino acid group Chemical group 0.000 description 21
- 230000035755 proliferation Effects 0.000 description 21
- 102100032543 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Human genes 0.000 description 20
- 101710132081 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Proteins 0.000 description 20
- 239000003814 drug Substances 0.000 description 20
- 102000006495 integrins Human genes 0.000 description 20
- 108010044426 integrins Proteins 0.000 description 20
- 210000002216 heart Anatomy 0.000 description 18
- 230000014509 gene expression Effects 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 16
- 230000006907 apoptotic process Effects 0.000 description 15
- 230000006378 damage Effects 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 238000010186 staining Methods 0.000 description 15
- 239000008194 pharmaceutical composition Substances 0.000 description 14
- 230000004913 activation Effects 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 13
- 208000028867 ischemia Diseases 0.000 description 13
- 229920001223 polyethylene glycol Polymers 0.000 description 13
- 230000001146 hypoxic effect Effects 0.000 description 12
- 230000036542 oxidative stress Effects 0.000 description 12
- 230000003247 decreasing effect Effects 0.000 description 11
- 229920000642 polymer Polymers 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 108020004705 Codon Proteins 0.000 description 10
- 125000000539 amino acid group Chemical group 0.000 description 10
- 210000001054 cardiac fibroblast Anatomy 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 230000007954 hypoxia Effects 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 230000010410 reperfusion Effects 0.000 description 10
- 230000017531 blood circulation Effects 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 229940124597 therapeutic agent Drugs 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 239000002202 Polyethylene glycol Substances 0.000 description 8
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 230000000069 prophylactic effect Effects 0.000 description 8
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 7
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 7
- 210000002744 extracellular matrix Anatomy 0.000 description 7
- 210000005003 heart tissue Anatomy 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 206010019280 Heart failures Diseases 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 108010029485 Protein Isoforms Proteins 0.000 description 6
- 102000001708 Protein Isoforms Human genes 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000000747 cardiac effect Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000011532 immunohistochemical staining Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 230000002107 myocardial effect Effects 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 231100000241 scar Toxicity 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000029663 wound healing Effects 0.000 description 5
- 239000004475 Arginine Substances 0.000 description 4
- 208000031229 Cardiomyopathies Diseases 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- 102000038030 PI3Ks Human genes 0.000 description 4
- 108091007960 PI3Ks Proteins 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 235000009697 arginine Nutrition 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000003683 cardiac damage Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 208000019622 heart disease Diseases 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004962 physiological condition Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000013042 tunel staining Methods 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 206010007559 Cardiac failure congestive Diseases 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 102100037813 Focal adhesion kinase 1 Human genes 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010063837 Reperfusion injury Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 230000021736 acetylation Effects 0.000 description 3
- 238000006640 acetylation reaction Methods 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 230000002491 angiogenic effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- -1 glycosylation Chemical compound 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 238000000099 in vitro assay Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000007914 intraventricular administration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 210000000651 myofibroblast Anatomy 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 208000020446 Cardiac disease Diseases 0.000 description 2
- 206010048610 Cardiotoxicity Diseases 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 2
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 2
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229940124783 FAK inhibitor Drugs 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 239000012828 PI3K inhibitor Substances 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- IDIDJDIHTAOVLG-VKHMYHEASA-N S-methylcysteine Chemical compound CSC[C@H](N)C(O)=O IDIDJDIHTAOVLG-VKHMYHEASA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 231100000259 cardiotoxicity Toxicity 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000034659 glycolysis Effects 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000002064 heart cell Anatomy 0.000 description 2
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 description 2
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000003147 molecular marker Substances 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 230000037387 scars Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000019432 tissue death Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical group NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
- 101001082567 Caenorhabditis elegans Hypoxia-inducible factor 1 Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000016680 Dioxygenases Human genes 0.000 description 1
- 108010028143 Dioxygenases Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000007201 Myocardial reperfusion injury Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 208000020584 Polyploidy Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- IDIDJDIHTAOVLG-UHFFFAOYSA-N S-methyl-L-cysteine Natural products CSCC(N)C(O)=O IDIDJDIHTAOVLG-UHFFFAOYSA-N 0.000 description 1
- NAQGHJTUZRHGAC-ZZZDFHIKSA-N SAICAR Chemical compound NC1=C(C(=O)N[C@@H](CC(O)=O)C(O)=O)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 NAQGHJTUZRHGAC-ZZZDFHIKSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102100036859 Troponin I, cardiac muscle Human genes 0.000 description 1
- 101710128251 Troponin I, cardiac muscle Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000006536 aerobic glycolysis Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000036570 collagen biosynthesis Effects 0.000 description 1
- 230000011382 collagen catabolic process Effects 0.000 description 1
- 230000001609 comparable effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000010393 epithelial cell migration Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000006203 ethylation Effects 0.000 description 1
- 238000006200 ethylation reaction Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 229940065115 grapefruit extract Drugs 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-O methylsulfide anion Chemical compound [SH2+]C LSDPWZHWYPCBBB-UHFFFAOYSA-O 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 231100001222 nononcogenic Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000007959 normoxia Effects 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000014306 paracrine signaling Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 230000003617 peroxidasic effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000009038 pharmacological inhibition Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 1
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 210000003281 pleural cavity Anatomy 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 210000003492 pulmonary vein Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000004728 pyruvic acid derivatives Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000037425 regulation of transcription Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 239000000717 tumor promoter Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
- 210000002620 vena cava superior Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Definitions
- This application relates in general to therapeutic methods for treating cardiovascular disorders. More particularly, this application relates to compositions, sy stems and methods for improving recovery and tissue repair following a cardiac injury by protecting cardiomyocytes and reducing cardiomyocyte death induced by cardiomyocyte injury' following myocardium damage. This application also relates to a pharmaceutical composition for treating or preventing or reducing cardiac fibrosis following myocardium damage, and more particularly, to a pharmaceutical composition for treating or preventing myocardium damage and the accompanying cardiac fibrosis.
- MI Acute myocardial infarction
- HF heart failure
- Cardiomyocytes are the primary cell type in an adult heart, responsible for maintaining its function.
- the loss of cardiomyocytes due to myocardial infarction stands as a significant factor for morbidity and mortality associated with heart diseases.
- the acute loss of cardiomyocytes caused by MI cannot be replaced, given the limited regenerative capability of adult cardiomyocytes. It is crucial to preserve cardiomyocytes to ensure patient survival after a heart attack.
- the death of cardiomyocytes swiftly activates a local tissue repair mechanism, prompting the engagement of cardiac fibroblasts. Once activated, cardiac fibroblasts produce an extracellular matrix (ECM), predominantly composed of collagen, forming scar tissue to avert myocardium rupture post-infarction.
- ECM extracellular matrix
- fibrosis is a reactionary process influenced by various factors. These factors include early inflammatory responses, a local surge in fibroblast cell populations, changes in the synthetic function of fibroblasts, and the altered dynamics of collagen biosynthesis and degradation. Other influential aspects comprise nearby tissue inflammation and a broad inflammatory state characterized by an uptick in circulating mediators. Unfortunately, no effective therapies exist to counteract cardiac fibrosis or to protect cardiomyocytes.
- This application provides a treatment for acute cardiac injuries, such as those resulting from heart attacks, and promotes cardiomyocyte proliferation.
- this application reveals that the administration of a recombinant PKM2 mutant (e.g., G415R; as referenced in Yan et al. "SAICAR activates PKM2 in its dimeric form,” published in Biochemistry, 2016 Aug 23; 55(33): 4731-4736), or a recombinant PKM2, or a protein identical or similar to pyruvate kinase M2 (PKM2) - which preferentially assumes the dimeric form - aids in preserving cardiomyocytes, spurs cardiomyocyte proliferation, and reduces cardiac fibrosis.
- PKM2 mutant e.g., G415R; as referenced in Yan et al. "SAICAR activates PKM2 in its dimeric form," published in Biochemistry, 2016 Aug 23; 55(33): 4731-4736
- PKM2 pyruvate kina
- the dimer form of PKM2 or its mutants can be administered (for instance, acutely) as a treatment for heart attacks.
- the dimeric form can be administered with other forms (e.g., the tetramer).
- a representative example of the recombinant PKM2 mutant suitable for the outlined methods is G415R, which chiefly adopts the dimeric form. Administering the recombinant PKM2 mutant can thwart cardiomyocytes from undergoing apoptosis and promote their proliferation under conditions such as hypoxia and oxidative stress.
- One aspect of the application encompasses a method of treating acute cardiac injury caused by acute cardiomyocyte loss in a patient or a subject.
- This method involves administering to the subject a composition containing pyruvate kinase M2 (PKM2) or a composition containing a mutant of PKM2. More specifically, a composition of PKM2 or a mutant of the same preferentially dimerizes at equilibrium can be administered to a subject within 1 to 10 hours following the cardiac injury.
- PKM2 pyruvate kinase M2
- Another aspect includes the administration of a recombinant PKM2 mutant (e.g., G415R) or a recombinant PKM2 (rPKM2) or a protein similar or identical to pyruvate kinase M2 (PKM2) to preserve cardiomyocytes during myocardial infarction, which shows that rPKM2 (the dimer mutant) is a therapeutic for heart attacks and other cardiovascular diseases.
- a recombinant PKM2 mutant e.g., G415R
- rPKM2 recombinant PKM2
- PKM2 pyruvate kinase M2
- the administration of rPKM2 or mutant thereof protects cardiomyocytes from death and promotes cardiomyocyte proliferation.
- recombinant PKM2 for example at a dosage that results in a concentration of rPKM2 of less than 1 micromolar to 5 micromolar in the patient’s blood stream
- a mutant that preferentially dimerizes decreases activation of cardiac fibroblasts, and therefore inhibits fibrosis, in the mice experiencing myocardial infarction and reperfusion injury .
- An ischemia/reperfusion protection composition as disclosed herein comprises a recombinant PKM2 mutant (e.g., G415R) or a recombinant PKM2 or a protein similar or identical to pyruvate kinase M2 (PKM2) that preferentially adopts the dimeric form.
- PKM2 mutant e.g., G415R
- PKM2 pyruvate kinase M2
- Another aspect includes a method of treating cardiac injury' in a subject that includes administering to the subject a therapeutically effective amount of either pyruvate kinase M2 (PKM2) or a PKM2 mutant within 10 hours of the cardiac injury.
- PKM2 or PKM2 mutant may be a dimer.
- Another aspect includes a method in which the PKM2 or PKM2 mutant dimerizes in the subject.
- Another aspect includes a method in which the administration occurs within 6 hours post cardiac injury or within 3 hours post cardiac injury or within 1 hour post cardiac injury.
- Another aspect includes a method in which the subject experienced a heart attack and the cardiac injury' is from the heart attack.
- Another aspect includes a method in which the PKM2 exists less than 50% in its tetrameric form.
- Another aspect includes a method in which the PKM2 predominantly forms a dimer at neutral pH.
- composition includes PKM2 or a mutant that of PKM2 that preferentially adopts a dimeric state.
- Another aspect includes a method in which the cardiac injury is caused by acute cardiomyocyte loss.
- Another aspect includes a method in which the myocardium preservation is achieved by administration of the composition.
- Another aspect includes a method in which the composition is delivered extracellularly.
- Another aspect includes a method in which the myocardial infarction is characterized as acute.
- composition comprises a PKM2 mutant or a protein highly similar to wild-type pyruvate kinase M2.
- Another aspect includes a method in which the PKM2 is from either a human or another animal.
- Another aspect includes a method in which the PKM2 has mutations differing from the wild-type sequence.
- composition is contained within a pharmaceutically acceptable carrier.
- compositions are delivered via intracardiac administration.
- Another aspect includes a method in which the composition is systemically delivered.
- Another aspect includes a method in which the composition mitigates cardiomyocyte death resulting from myocardial infarction.
- Another aspect includes a method in which the composition decreases cardiac fibrosis in the infarcted myocardium.
- Another aspect includes a method in which the pyruvate kinase M2 predominantly exists as a dimer compared to its tetrameric form.
- Another aspect includes a method in which the PKM2 features a G415R mutation.
- Another aspect includes a method in which the PKM2 or the PKM2 mutant is in the extracellular space.
- FIG. 1 A illustrates that recombinant G415R protected H9C2 cells from apoptosis under hypoxic conditions.
- FIG. IB demonstrates that recombinant G415R promoted cell proliferation under hypoxic conditions.
- FIG. 1C indicates that recombinant G415R had comparable effects on primary human cardiomyocytes and protected them from apoptosis under both hypoxia and oxidative stress conditions.
- FIGs ID and IE reveal that recombinant G415R promoted the proliferation of primary cardiomyocytes under hypoxic and oxidative stress conditions.
- FIG. 2A highlights that the administration of recombinant G415R substantially reduced mortality in MI mice at all observed time points.
- FIG. 2B presents that the administration of recombinant G415R lowered the heart weight (relative to body weight) in MI mice 30 days post-infarction.
- FIGs. 3 A and 3B depict histological analyses of infarcted hearts, showing that mice treated with recombinant G415R had smaller infarction scar sizes compared to the rPKMl and vehicle-treated groups in both MI and IR models.
- FIGs. 3C, 3G, and 3H show that recombinant G415R protects cardiomyocytes from apoptosis, as evidenced by TUNEL staining of heart tissues at 6-, 24-, and 168-hours postinfarction, respectively.
- FIG. 3D indicates that cardiomyocyte apoptosis was minimally observed via TUNEL staining of myocardial tissues 168 hours post-infarction.
- FIG. 3E demonstrates that in G415R-treated mice, cardiomyocyte proliferation was evident in myocardial tissue of both MI and IR models at days 4 and 7 post-infarction.
- FIG. 3F shows that G415R treatments significantly reduced cTnl levels in the bloodstream of infarcted mice 7 days post-infarction.
- FIG. 4A shows wheat germ agglutinin (WGA) staining of myocardial tissue, indicating that G415R-treated mice exhibited fewer infarction scars in the myocardium's infarcted regions in both MI and IR models compared to rPKMl and vehicle-treated groups.
- FIGs. 4B and 4C illustrate analyses of cardiomyocyte (cross-sectional area) by WGA and cTnl co-staining, suggesting that recombinant G415R treatment reduced the cardiomyocyte cross-sectional area to levels similar to the sham groups in MI mice.
- FIGs. 4D and 4E show analyses of cardiomyocyte (cross-sectional area) by WGA and cTnl co-staining, revealing that G415R treatment decreased cardiomyocyte cross-sectional area to levels similar to the sham groups in IR mice, signifying significantly reduced cardiomyocyte hypertrophy.
- FIGs. 4F and 4G depict that G415R reduced the activation of cardiac myofibroblasts in the infarcted myocardium of MI and IR mice (observed at 30 days) as indicated by IHC staining of a-SMA.
- FIGs. 5A-5D show that G415R decreased PTEN expression in both cultured cardiomyocyte cells (evidenced by immunoblotting) and myocardial tissue (IHC staining) of infarcted mice.
- administration refers to providing or delivering a therapeutic agent (e.g., an agent as described herein) to a subject by any effective route.
- the composition is administered into the same subject by multiple routes of administration.
- the multiple routes of administration comprise intravenous administration, intraarterial administration, intrathecal administration, intranasal administration, intraperitoneal administration, and/or periocular administration.
- the composition having PKM2 or a mutant of the same can be administered intravenously to the circulatory’ system of the subject.
- the composition having PKM2 or a mutant of the same can be infused in suitable liquid and administered into a vein of the subject.
- acute myocardial infarction and "heart attack” refer to a condition where localized myocardial ischemia leads to the development of a defined region of tissue death.
- An acute myocardial infarction is most commonly caused by the rupture of an atherosclerotic lesion in a coronary artery. This rupture results in the formation of a thrombus that occludes the artery', preventing it from supplying blood to the region of the heart it serves.
- amino acid refers to naturally occurring and non-natural amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids.
- Naturally encoded amino acids are the 20 common amino acids (alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine) and pyrolysine and selenocysteine.
- Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, by way of example only, an a-carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group. Such analogs may have modified R groups (by way of example, norleucine) or may have modified peptide backbones, while still retaining the same basic chemical structure as a naturally occurring amino acid.
- Non-limiting examples of amino acid analogs include homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium.
- “conservatively modified variants” applies to both natural and non-natural amino acid sequences and natural and non-natural nucleic acid sequences, and combinations thereof.
- “conservatively modified variants” refers to those natural and non-natural nucleic acids which encode identical or essentially identical natural and non-natural amino acid sequences, or where the natural and non-natural nucleic acid does not encode a natural and non-natural amino acid sequence, to essentially identical sequences.
- the codons GCA, GCC, GCG and GCU all encode the amino acid alanine.
- nucleic acid variations are “silent variations,” which are one species of conservatively modified variations.
- every' natural or non-natural nucleic acid sequence herein which encodes a natural or non-natural poly peptide also describes every possible silent variation of the natural or non- natural nucleic acid.
- each codon in a natural or non-natural nucleic acid can be modified to yield a functionally identical molecule. Accordingly, each silent variation of a natural and non-natural nucleic acid which encodes a natural and non-natural polypeptide is implicit in each described sequence.
- MI myocardial infarction
- Ischemia refers to local deficiency of blood supply, generally produced by vasoconstriction or local obstacles to blood flow. Restoration of blood flow to a previously ischemic tissue or organ, such as the heart is referred to as “reperfusion.”
- ischemia reperfusion refers to the damage caused to tissue when blood supply returns to the tissue after a period of ischemia.
- the absence of oxygen and nutrients from blood creates a condition in which the restoration of circulation results in inflammation and oxidative or peroxidative damage.
- nucleic acid sequence refers to the order and identity of the nucleotides comprising a nucleic acid.
- Nucleic acid refers to deoxyribonucleotides or ribonucleotides and polymers thereof in single- or double-stranded form.
- the term encompasses nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non-naturally occurring, which have similar binding properties as the reference nucleic acid, and which are metabolized in a manner similar to the reference nucleotides. Examples of such analogs include, without limitation, phosphorothioates, phosphoramidates, methyl phosphonates. chiral-methyl phosphonates, 2-O-methyl ribonucleotides, peptidenucleic acids (PNAs).
- nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences, as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues.
- nucleic acid is used interchangeably with gene, cDNA, mRNA, oligonucleotide, and polynucleotide.
- a particular nucleic acid sequence also implicitly encompasses “splice variants.”
- a particular protein encoded by a nucleic acid implicitly encompasses any protein encoded by a splice variant of that nucleic acid.
- “Splice variants,” as the name suggests, are products of alternative splicing of a gene. After transcription, an initial nucleic acid transcript may be spliced such that different (alternate) nucleic acid splice products encode different polypeptides.
- Mechanisms for the production of splice variants vary, but include alternate splicing of exons. Alternate polypeptides derived from the same nucleic acid by read-through transcription are also encompassed by this definition. Any products of a splicing reaction, including recombinant forms of the splice products, are included in this definition.
- polypeptide “peptide” and “protein” are used interchangeably herein to refer to a polymer of amino acid residues.
- the terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymer.
- pharmaceutically acceptable refers to a material, including but not limited, to a salt, carrier or diluent, which does not abrogate the biological activity or properties of the compound, and is relatively nontoxic, i.e., the material may be administered to an individual without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.
- prophylactically effective amount refers that amount of a composition containing at least one non-natural amino acid polypeptide or at least one modified non-natural amino acid polypeptide prophylactically applied to a patient which will relieve to some extent one or more of the symptoms of a disease, condition or disorder being treated. In such prophylactic applications, such amounts may depend on the patient's state of health, weight, and the like. It is considered well within the skill of the art for one to determine such prophylactically effective amounts by routine experimentation, including, but not limited to, a dose escalation clinical trial.
- the substantial identity' exists over a region of the sequences that is at least about 10, preferably about 20.
- a substantially similar polypeptide or nucleic acid may be that of a mutant or other protein that preferentially adopts the dimeric form.
- the more effective proteins preferentially dimerized and w ere soluble.
- synergistic refers to a combination of prophylactic or therapeutic effective agents which is more effective than the additive effects of any two or more single agents.
- a synergistic effect of a combination of prophylactic or therapeutic agents may permit the use of low er dosages of one or more of the agents and/or less frequent administration of the agents to a subject with a specific disease or condition.
- a synergistic effect of a combination of prophylactic or therapeutic agents may be used to avoid or reduce adverse or unwanted side effects associated with the use of any single therapy.
- the term “therapeutically effective amount,'’ refers to the amount of a composition or biologic containing the protein administered to a patient already suffering from a disease, condition or disorder, sufficient to cure or at least partially arrest, or relieve to some extent one or more of the signs, symptoms or causes of the disease, disorder or condition being treated.
- the effectiveness of such compositions depends on the conditions including, but not limited to, the severity and course of the disease, disorder or condition, previous therapy, the patient's health status and response to the drugs, and the judgment of the treating physician.
- therapeutically effective amounts may be determined by routine experimentation, including but not limited to a dose escalation clinical trial.
- the term “effective amount” is meant to include any amount of a composition or biologic, such as pyruvate kinase M2 or variant thereof, that is sufficient to bring about a desired therapeutic result.
- Therapeutically effective amount in the context of using a composition to treat heart cells after a heart attack, refers to the quantity of the composition that, when administered to an individual, produces the desired therapeutic effect to alleviate, mitigate, or reverse the damage to the heart cells caused by the heart attack. This amount can vary based on factors such as the specific composition, the severity of the heart attack, the patient's overall health, age, weight, and other medical considerations. In a typical subject of typical body weight, the therapeutically effective amount can range from 0. 1 to 10 mg/ml intravenously, or from 0.5 to 7 mg/ml intravenously, from 0. 1 to 6 mg/ml intravenously, or from 4 to 6 mg/ml intravenously or about 5 mg/ml intravenously.
- the dose can be administered as a single acute treatment or delivered gradually over a specified duration (e.g at for 5 minutes to 5 hours or more).
- subj ect or “patient” as used herein includes mammals and humans.
- the patient is having a heart attack.
- dosage refers to the amount of a composition or biologic, such as pyruvate kinase M2 or variant thereof, administered to an animal or human or utilized in a cell culture assays.
- Suitable dosage units for use in the methods of the present invention include, but are not limited to, ng/kg body weight, mg/kg, mg/kg/day, M, nM, pM, or any other unit otherwise referred to in this disclosure or commonly used in the art. In one example, 5 mg/ml is administered.
- therapeutic agent encompasses proteins, peptides, nucleic acids, vectors, pharmacological agents, or other macromolecules or compositions that are known in the art.
- the therapeutic agent may be delivered to the recipient via inhalation, oral administration, subcutaneous injection; intraperitoneal injection, intravenous injection, intramuscular injection, intradermal injection, or any other method of agent delivery used in the art.
- Agents may be delivered as a single bolus or other one-time administration mechanisms; alternatively, agents may be administered via a sustained (continuous or intermittent) delivery.
- the terms ’‘treat,” “treatment,” “treating,” and the like, refer to obtaining a desired pharmacologic and/or physiologic effect, including without limitation achieving amelioration, improvement, or elimination of symptoms of ischemia.
- the effect may be prophylactic in terms of completely or partially preventing cardiac fibrosis and/or may be therapeutic in terms of ameliorating, improving, or eliminating one or more symptoms of cardiomyocyte damage.
- Treatment covers any treatment of acute myocardial infarction in a mammal, particularly in a human, and includes: (a) preventing the cardiac fibrosis from occurring in a subject; (b) relieving the cardiac fibrosis; and (c) restoring the individual to a pre-cardiac event state. “Treatment” may not indicate, or require, complete eradication or cure of the acute myocardial infarction, or associated symptoms thereof.
- PKM2 refers to pyruvate kinase isoform M2.
- PKM2 mutant as used throughout this specification, variant form of the pyruvate kinase M2 (PKM2) protein, in which one or more amino acid residues have been altered, added, or removed in comparison to the native or wild- type PKM2 sequence.
- PKM2 pyruvate kinase M2
- These alterations can be the result of genetic mutations, or they can be artificially introduced through methods such as genetic engineering. Mutations can lead to changes in the protein's function, stability, interaction partners, or other properties and
- the application provides methods for treating and/or preventing a cardiac disease in a subj ect in need thereof.
- the present inventors have made intensive research efforts to develop a method for protecting cardiomyocytes from death (e.g., apoptosis) and preventing or reducing cardiac fibrosis or heart disease accompanying cardiac fibrosis.
- Specific embodiments are directed to protecting cardiomyocytes and promoting the growth of cardiomyocytes.
- Cardiac disease that can be treated include cardiomyopathy, such as hypertrophic cardiomyopathy, dilated cardiomyopathy, and toxic cardiomyopathy; cardiotoxicity; congestive heart failure; and cardiac damages due to some infectious e g., virus or bacteria.
- One embodiment is a method of reducing an adverse consequence of myocardial infarction in a patient comprising administering a composition having a recombinant PKM2 mutant (e.g., G415R), or a recombinant PKM2 or a protein similar or identical to PKM2 that preferentially adopts the dimeric form or has a least some dimeric form of PKM2, to the patient during the acute stage of the myocardial infarction.
- the therapeutic PKM2 is not PKM2 that exists primarily as a tetramer.
- the therapeutic PKM2 is not expressed intracellularly, e.g., as a result of transfection of cardiomyocytes with a nucleic acid encoding PKM2.
- the PKM2 or PKM2 mutant in the composition has a dimer form or exists as a dimer at least is some part.
- the period immediately after heart injury or heart trauma is critical and is sometimes referred to as the “golden hour” or the first hour following a myocardial infarction.
- the myocardial infarction can be an acute myocardial infarction.
- Administration of the ischemia/reperfusion protection composition may be commenced within 200 hours of onset of a heart attack.
- the protein substantially similar or identical to pyruvate kinase M2 PLM2
- PLM2 protein substantially similar or identical to pyruvate kinase M2
- the patient can be a human or a non-human mammal.
- An ischemia/reperfusion protection composition as disclosed herein comprises a protein similar or identical to PKM2 at a dosage that results in a concentration of ⁇ 1pm to 5 pm under physiological conditions in a patient’s blood stream or a mutant PKM2 that exists primarily in dimeric form.
- PKM2 administered such that it is at a concentration of ⁇ 1pm under physiological conditions in a patient will exist as about 70-85% dimer.
- PKM2 administered such that it is at a concentration of > 10 pm under physiological conditions in a subject will exists as ⁇ 25% dimer.
- a 5 mg/ml concentration as the drug formulation for patient administration will be approximately 100 pm in dosage form but will be diluted to ⁇ 5 pm once it is administered and is in the patient’s blood circulation.
- PKM2 mutant G415R exists as > 85% dimer at concentrations that are > 50 pm.
- the invention discloses, in part, administering an effective amount of a therapeutic composition to a subject to protect cardiomyocytes or promote growth of cardiomyocytes.
- a therapeutic composition comprising at least 51% dimer, at least 60% dimer, at least 70% dimer, at least 80% dimer or at least 90% dimer.
- the composition reduces cardiomyocyte death induced by cardiac injury.
- the invention discloses a method of reducing or inhibiting cardiac fibrosis by administering a composition comprising recombinant wild type PKM2 in an amount that results in a concentration of wt PKM2 of ⁇ 1pm in the bloodstream after administration to a patient.
- the invention discloses a method of reducing or inhibiting cardiac fibrosis by administering r a composition comprising a mutant of PKM2 that preferentially dimerizes at equilibrium. Without intending to be bound to a particular mechanism, it is postulated that the reduction in fibrosis is a result of reduced cardiomyocyte death.
- PKM2 mutants have a least 75%, preferably at least 85%, more preferably at least 90%, 95%, 98%, 99% or higher or any integral value therebetween nucleotide or amino acid residue identity when compared to wild-type PKM2.
- PKM2 mutants that preferentially adopt the dimeric form are useful in the methods and systems for treating MI, IR and other conditions related to cardiomyocyte injury.
- composition and methods are directed to cardiac conditions that involve damaged cardiac tissue such as damage cardiac muscles arising from ischemic events, ischemia reperfusion injury, damage to the left ventricle such as those arising from congestive heart failure, damage to the heart valves arising from diseases, such as coronary artery’ diseases.
- damaged cardiac tissue such as damage cardiac muscles arising from ischemic events, ischemia reperfusion injury, damage to the left ventricle such as those arising from congestive heart failure, damage to the heart valves arising from diseases, such as coronary artery’ diseases.
- PKM2 damage to the left ventricle
- diseases such as coronary artery
- the composition may be administered with another agent.
- an agent can include a hypolipidemic drug, an antiplatelet drug, a blood pressure lowering drug, a dilated vascular drug, a hypoglycemic drug, an anticoagulant drug, a thrombolytic drug, a liver protection drug, anti arrhythmic drugs, cardiotonic drugs, diuretic drugs, anti -infective drugs, antiviral drugs, immunomodulatory’ drugs, inflammatory’ regulating drugs, anti-tumor drugs, or hormone drugs.
- Pyruvate kinase isoform M2 (PKM2) is a pyruvate kinase isoform expressed in mammalian cells. Pyruvate kinase regulates the final rate-limiting event of glycolysis by catalyzing the transfer of a phosphate group from phosphoenolpyruvate to ADP to produce pyruvate and ATP.
- PKM1 and PKM2 are ubiquitously expressed in different types of cells and tissues. PKM2 is highly expressed in proliferating cells including cancer cells.
- PKM2 is a unique multifaceted regulator that can improve cells adaptation in their metabolic program to match physiological needs in different environments.
- PKM2 In addition to regulating glycolysis, PKM2 has non-metabolic functions such as regulation of transcription and cell cycle progression. In contrast to the mitochondrial respiratory reaction, energy regeneration by these pyruvate kinases is independent from oxygen supply and allow s survival of the organs under hypoxic conditions. PKM2 may also act as a co-activator of hypoxia-induced factor 1 -alpha (HIF-la); the latter behaves as a master transcription factor to regulate multiple signaling pathways in response to hypoxic insults. Increased levels and activities of PKM2 are associated with enhanced motility and metastasis of tumor cells; the molecular mechanism of the increased cell migration is so far poorly understood.
- hypoxia-induced factor 1 -alpha HIF-la
- the angiogenic activity and/or endothelial cell proliferative or migration potential of a pyruvate kinase M2, or a therapeutic substantially similar to pyruvate kinase can be assessed by assays and methodology.
- the pyruvate kinase protein can be any vertebrate or mammalian pyruvate kinase, and may be a native pyruvate kinase, or a recombinant or other synthetic protein.
- the amino acid sequence for human pyruvate kinase is for instance provided by GenBank Accession No. MP0011193727 pyruvate kinase.
- amino acid sequence identity of pyruvate kinase for example is highly conserved between species with human having 98% amino acid sequence identity with mouse, hamster, and rat.
- the amino acid sequence for human pyruvate kinase is disclosed herein (Example 1).
- active pyruvate kinase protein is a dimer, also known as PKM2 subtype M2.
- PKM2 subtype M2 A broad range of proteins and therapeutics substantially similar to pyruvate kinase M2 are useful with specific embodiments.
- An animal from which native pyruvate kinase protein is purified can for instance be a member of the bovine, ovine, porcine, equine, canine, feline, primate, rodent or other mammalian family.
- the pyruvate kinase protein will be a human pyruvate kinase protein purified from bacterial production.
- a recombinant pyruvate kinase protein can have an identical amino acid sequence to the native pyruvate kinase or one or more amino acid differences compared to the native protein.
- the amino acid changes can comprise the addition, deletion and/or substitution of one or more amino acids. Inversion of amino acids and other mutational changes that result in modification of the native pyruvate kinase protein sequence are also encompassed.
- a recombinant protein can comprise an amino acid or amino acids not encoded by the genetic code.
- the substitution of an amino acid can be a conservative or non-conservative substitution.
- conservative amino acid substitution is to be taken in the normally accepted sense of replacing an amino acid residue with another amino acid having similar properties, which does not have a substantial and adverse effect the angiogenic and/or wound healing activity of the pyruvate kinase protein.
- a conservative amino acid substitution can involve substitution of a basic amino acid such as arginine with another basic amino acid such as lysine.
- a cysteine residue can be replaced with serine, or a non-polar amino acid may be substituted with another non-polar amino acid such as alanine.
- Amino acids amenable to substitution or deletion in a pyruvate kinase protein amino acid sequence may be determined by comparison of the sequence with closely related pyruvate kinase proteins to identify non-conserved amino acids and by routine trial and experimentation well within the skill of the addressee.
- a modified recombinant pyruvate kinase protein can be provided by introducing nucleotide change(s) in nucleic acid sequence encoding the native protein such that the desired amino acid changes are achieved upon expression of the nucleic acid in a host cell.
- One embodiment includes an a recombinant or other synthetic PKM2 that preferentially dimerizes.
- Such recombinant or other synthetic PKM2 includes the PKM2 G415R mutant.
- the amino acid sequence of the G415R mutant is shown in Example 2 and also SEQ ID NO: .
- Variants of PKM2 or mutants of the same that are more useful are those that preferentially adopt the dimeric form and are soluble in water.
- PKM2 (Accession No. NP 002645) is as follows:
- 181 islqvkqkga dflvteveng gslgskkgvn Ipgaavdlpa vsekdiqdlk fgveqdvdmv 241 fasfirkasd vhevrkvlge kgknikiisk ienhegvrrf deileasdgi mvargdlgie
- 181 islqvkqkga dflvteveng gslgskkgvn Ipgaavdlpa vsekdiqdlk fgveqdvdmv 241 fasfirkasd vhevrkvlge kgknikiisk ienhegvrrf deileasdgi mvargdlgie
- Another exemplary mutant pyruvate kinase M2 amino acid sequence having three mutations (R399E, K422A, and N523A) or SEQ ID NO: 3 is as follows;
- a recombinant or synthetic pyruvate kinase protein suitable for the methods of this invention should exhibit an amino acid sequence identity with native pyruvate kinase of at least 60%. More commonly, the identity may be at least 70%, 80%, 90%, 95%, 98%, or even 100%. Some of the protein must fonn a dimer under physiological conditions in a patient. All sequence homologies and ranges specified above are explicitly included. Sequence identity between amino acid sequences is determined by comparing amino acids at each position in optimally aligned sequences. Amino acids at a given position are considered identical only if they match.
- a gap — where an amino acid residue appears in one sequence but not in another — is treated as a position with non-identical residues.
- Aligning sequences can be achieved using any appropriate program or algorithm, with computer-assisted sequence alignments ty pically performed using standard software.
- the pyruvate kinase protein can also be chemically synthesized.
- the creation and use of fusion proteins incorporating a pyruvate kinase protein, as described herein, are also encompassed by the invention.
- Nucleic acids encoding a fusion protein can be generated by joining separate DNA fragments encoding the pyruvate kinase protein and, for instance, a lipophilic amino acid sequence to enhance the lipophilic characteristics of the protein. This can be achieved using methods such as employing blunt-endedtemiini and oligonucleotide linkers, digestion to provide staggered termini, and ligation of cohesive ends as required.
- Pyruvate kinase proteins described herein can also be modified by coupling one or more proteinaceous or non-proteinaceous moieties to the protein. This improves aspects like solubility, lipophilic characteristics, stability, biological half-life, or serves as a label for subsequent detection. Modifications can arise from post-translational or post-synthesis processes such as the attachment of carbohydrate moieties or chemical reactions leading to structural modifications (e.g., alky lation or acetylation of amino acid residues).
- the pyruvate kinase protein may undergo modifications like methylation, phosphorylation, oxidation of tyrosine and/or tryptophan residues, glycosylation, or S-methylcysteine covalent attachment.
- the pyruvate kinase protein can vary in size from the complete protein. However, the pyruvate kinase should be of a length that facilitates dimer formation.
- Both intact and truncated forms of the protein might undergo post-translational modifications, including but not limited to acetylation, methylation, ethylation, phosphorylation, oxidation, and glycosylation, found in the native pyruvate kinase protein.
- Suitable conditions for alkaline phosphatase activity include the presence of zinc, magnesium, or calcium-containing buffers.
- Partially hydrolyzed forms of pyruvate kinase proteins can be purified for use in the invention's embodiments using any appropriate purification technique, including filtration and chromatography protocols.
- the pyruvate kinase protein can be administered to a subject in need of such treatment alone or be co-administered with one or more other therapeutic agents.
- pyruvate kinase can be co-administered in combination with therapeutic agents conventionally used for promoting angiogenesis, cellular proliferation, or wound healing.
- co- administered is meant simultaneous administration in the same formulation or in two different formulations by the same or different routes, or sequential administration by the same or different routes, whereby the pyruvate kinase protein and other therapeutic agent(s) exhibit overlapping therapeutic windows.
- ‘'sequential” administration is meant one is administered after the other.
- Such further agents that may be co-administered with the pyruvate kinase protein include platelet-derived growth factor (PDGF), transforming growth factor-.beta. (TGF-0), platelet- derived wound healing factor, insulin growth factor (IGF), keratinocyte gro th factor (KGF), anti-inflammatory agents and anti-microbial agents.
- PDGF platelet-derived growth factor
- TGF-0 transforming growth factor-.beta.
- IGF insulin growth factor
- KGF keratinocyte gro th factor
- anti-inflammatory agents anti-microbial agents.
- therapeutic agents used for promoting angiogeneisis and/or wound healing include indoleamine 2,3-dioxygenase (IDO), tryptophan dioxygenase (TDO), spingosine-1 -phosphate (SIP), N- acylethanolamines, grapefruit extract and other plant phytochemicals including ascein, green tea catechins, melatonin, arginine and other amino acids for support of vessel growth. Additional therapeutic agents appropriate for co-admini strati on will be obvious to those of ordinary skill in the art.
- the pyruvate kinase protein will generally be formulated into a pharmaceutical composition comprising the protein and a pharmaceutically acceptable carrier.
- a pharmaceutical composition as described herein can also incorporate one or more preservatives such as parabens, chlorobutanol, and sorbic acid, binders such as com starch or gelatin, thickening agents, emulsifiers, surfactants, gelling agents, and other components typically used in such compositions.
- Pharmaceutically acceptable carriers include any suitable conventionally known physiologically acceptable solvents, dispersion media, isotonic preparations and solutions. Use of such ingredients and media for pharmaceutically active substances is w ell known. Except insofar as any conventional media or agent is incompatible with the pyruvate kinase protein, use thereof is expressly encompassed.
- compositions embodied by the invention include therapeutic compositions for human or veterinary use.
- a pharmaceutical composition embodied by the invention will generally contain at least about 0.001% by weight of the pyruvate kinase protein up to about 80% w/w of the composition.
- the pharmaceutical composition can contain about 0.05%, 0.01%, 0.1%, 1%, 10%, 20%, 30%, 40%. 50%. 60%. 70%. or 80% by weight of the pyruvate kinase protein, substantially similar therapeutic or mutant PKM2 that preferentially dimerizes.
- a pharmaceutical composition embodied by the invention will generally contain at least about 20pg/ml of the pyruvate kinase protein up to about 1000 pg/ml.
- the pharmaceutical composition can contain about 50pg/ml, 60pg/ml, 70pg/ml, 80pg/ml, 90pg/ml, lOOpg/ml, 200pg/mL 300pg/ml, 400pg/mL 500pg/ml, 600pg/ml, 700pg/ml, 800pg/ml, 900
- the amount of the protein in the composition will be such that a suitable effective dosage will be delivered to the subject taking into account the proposed mode of administration.
- the dosage of the pyruvate kinase protein administered in accordance with an embodiment of the invention will depend on a number of factors including whether the protein is to be administered for prophylactic or therapeutic use, the disease or condition for which the protein is intended to be administered, the severity of the condition, the sex and age of the subject, and related factors including weight and general health of the subject, and can be determined in accordance with accepted medical principles. For instance, a low' dosage can initially be given which is subsequently increased at each administration following evaluation of the subject's response. Similarly, the frequency of administration can be determined in the same way that is, by continuously monitoring the subject's response betw een each dosage and if desirable, increasing the frequency of administration or alternatively, reducing the frequency of administration.
- the dosage may be between 1 mg/kg and 20 mg/kg; in another example, the dosage may be between 2 mg/kg and 10 mg/kg; in another example, the dosage may be between 1 mg/kg and 6 mg/kg; and in yet another example, the dosage may be between 2 mg/kg and 5 mg/kg.
- Routes of administration include but are not limited to topically, respiratorialy, intravenously, orally, intraperitoneally, subcutaneously, intramuscularly, rectally, topically, directly into the heart, and by implant.
- intravenous routes particularly suitable routes are via injection into blood vessels (e.g., superior and inferior vena cava) which supply the target tissue to be treated.
- the pyruvate kinase protein can also be delivered into cavities such as for example the pleural or peritoneal cavity, cranial or be injected directly into the tissues to be treated, e.g., the left or right ventricle of the heart.
- the pyruvate kinase protein can be encapsulated or otherwise provided in an enteric for passage through the stomach and release in the small intestine. Any suitable such enteric formulation or coating can be utilized. Furthermore, these systems and methods may be practiced using any mode of administration that is medically acceptable, meaning any mode that produces effective levels of cellular regeneration or tissue repair without causing clinically unacceptable adverse effects.
- a pyruvate kinase protein can also be coated onto the surface of a stent or balloon of a catheter such as an angioplasty catheter, or other surgical instrument for application to the interior wall of a blood vessel during angioplasty or other surgical procedure.
- the pyruvate kinase can for instance be applied to the wall of the blood vessel in this manner in the form of a gel or any other appropriate formulation to promote wound healing and/or angiogenesis, epithelial cell migration, or cellular regeneration at the site of treatment.
- Suitable pharmaceutically acceptable carriers and formulations useful in compositions embodied by the invention can for instance be found in handbooks and texts.
- Pharmaceutical agents include the following categories and specific examples. It is not intended that the category be limited by the specific examples. Those of ordinary skill in the art will be able to identify readily those phannaceutical agents that have utility within or outside of the central nervous system. Those of ordinary skill in the art will recognize also numerous other compounds that fall within the categories and that are useful according to the invention.
- One embodiment also includes a kit for improving recovery following a cardiac episode or injury.
- the combination of agents is provided to allow administration in an amount and frequency therapeutically effective to produce cellular regeneration following a cardiac episode or injury.
- polyethylene glycol may be used to derivatize polypeptides of the invention, include, for example, poly (ethylene glycol) (PEG), poly (vinylpyrrolidone), polyoxomers, polysorbate and poly(vinyl alcohol), with PEG polymers being particularly preferred.
- PEG polymers are PEG polymers having a molecular weight of from about 100 to about 40,000.
- Other suitable hydrophilic polymers in addition to those exemplified above, will be readily apparent to one skilled in the art based on the present disclosure.
- the polymers used may include polymers that can be attached to the polypeptides of the invention via alkylation or acylation reactions.
- the PKM2 or a substantially similar therapeutic was PEGylated with a PEG-chain of 20 kDa.
- polyethylene glycol may be covalently bound through amino acid residues via a reactive group, such as, a free amino or carboxyl group.
- Reactive groups are those to which an activated polyethylene glycol molecule may be bound.
- the amino acid residues having a free amino group may include lysine residues and the N-terminal amino acid residues; those having a free carboxyl group may include aspartic acid residues glutamic acid residues and the C- terminal amino acid residue.
- Sulfhydryl groups may also be used as a reactive group for attaching the polyethylene glycol molecules.
- Preferred for therapeutic purposes is attachment at an amino group, such as attachment at the N-terminus or lysine group.
- polyethylene glycol as an illustration of the present composition, one may select from a variety of polyethylene glycol molecules (by molecular weight, branching, etc.), the proportion of polyethylene glycol molecules to polypeptide (polypeptide) molecules in the reaction mix, the type of pegylation reaction to be performed, and the method of obtaining the selected N-terminally pegylated polypeptide. Under the appropriate reaction conditions, substantially selective derivatization of the polypeptide at the N-terminus with a carbonyl group containing polymer is achieved.
- compositions comprise a therapeutically effective amount of active component (e.g., PKM2 dimer, PKM2 mutant that exists more as a dimer than as a tetramer, or a substantially similar therapeutic), and a pharmaceutically acceptable carrier.
- active component e.g., PKM2 dimer, PKM2 mutant that exists more as a dimer than as a tetramer, or a substantially similar therapeutic
- pharmaceutically acceptable carrier can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for inj ectable solutions.
- Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.
- the composition if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like.
- the composition can be formulated as a suppository', with traditional binders and carriers such as triglycerides.
- Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc.
- Such compositions will contain a therapeutically effective amount of the PKM2 or a substantially similar therapeutic together with a suitable amount of carrier so as to provide the form for proper administration to the patient.
- the formulation should suit the mode of administration.
- the amount of the PKM2 or a substantially similar therapeutic that will be effective in assisting with recovery from an ischemic episode can be determined by standard clinical techniques.
- in vitro assays may optionally be employed to help identify optimal dosage ranges.
- the precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems.
- the agent or pharmaceutical compositions can be tested in vitro, and then in vivo for the desired therapeutic or prophylactic activity, prior to use in humans.
- in vitro assays to demonstrate the therapeutic or prophylactic utility of a compound or pharmaceutical composition include the effect of a compound on a cell line or a patient tissue sample.
- the effect of the compound or composition on the cell line and/or tissue sample can be determined utilizing techniques known to those of skill in the art including, but not limited to, rosette formation assays and cell lysis assays.
- in vitro assays which can be used to determine whether administration of a specific compound is indicated, include in vitro cell culture assays in which a patient tissue sample is gro ⁇ n in culture, and exposed to or otherwise administered a compound, and the effect of such compound upon the tissue sample is observed.
- compositions for intravenous administration are solutions in sterile isotonic aqueous buffer.
- the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection.
- the ingredients are supplied either separately or mixed together in unit dosage fonn, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachet indicating the quantity of active agent.
- composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline.
- an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.
- Various delivery systems are known and can be used to administer a compound of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the compound, receptor-mediated endocytosis, construction of a nucleic acid as part of a retroviral or other vector, etc.
- Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal. epidural, and oral routes.
- the compounds or compositions may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local.
- the therapeutic composition ischemia/reperfusion protection composition
- This may be achieved by. for example, and not by way of limitation, local injection (for example, injection into the myocardium) or infusion during surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non- porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers.
- regulatory genes and sequence may be used with the expression and replication of the PKM2 or a substantially similar therapeutic.
- the nature of the regulatory sequences for gene expression may vary between species or cell types, but shall in general include, as necessary. 5' non-transcribing and 5' non-translating sequences involved with initiation of transcription and translation respectively, such as a TATA box, capping sequence, CAAT sequence, and the like. Promoters may be constitutive or inducible. Regulatory sequences may also include enhancer sequences or upstream activator sequences, as desired.
- polynucleotides encoding the PKM2 or a substantially similar therapeutic may be fused to polynucleotides encoding signal sequences which will direct the localization of a polypeptide to particular compartments of a prokaryotic or eukaryotic cell and/or direct the secretion of a polypeptide.
- signal sequences which will direct the localization of a polypeptide to particular compartments of a prokaryotic or eukaryotic cell and/or direct the secretion of a polypeptide.
- E. coli one may wish to direct the expression of the protein to the periplasmic space.
- vectors are commercially available for the construction of fusion proteins which will direct the localization of a protein.
- stents that comprise a generally tubular structure, which may include, for example, spiral shapes.
- the surface of this structure is coated with PKM2 or a therapeutic that is substantially similar, as described above.
- a stent is ty pically a scaffolding, usually cylindrical in shape, which can be inserted into a body passageway (e.g., bile ducts, arteries, veins) or a portion thereof.
- This passageway may have been narrowed. irregularly contoured, obstructed, or occluded due to a disease process (e.g., tumor ingrow th) to prevent the closure or reclosure of the passageway.
- One specific embodiment also provides use of PKM2 or a substantially similar therapeutic in a wide variety of surgical procedures.
- surgical meshes which have been coated with PKM2 may be utilized in any procedure wherein a surgical mesh might be utilized.
- the following is an exemplary wild-type pyruvate kinase M2 amino acid sequence or SEQ ID NO: 4 .
- integrin a v p3 is expressed in cardiomyocytes under cardiac infarction condition.
- the inventors probed the expression of the integrin in H9C2 cells by immunofluorescence (IF) staining. Integrin was expressed in high levels in the cells under hypoxia condition and not under normoxia condition. Further, the inventors analyzed the integrin expression in primary human cardiomyocytes under hypoxia and oxidative stress conditions. The integrin was expressed in cardiomyocytes under the stress conditions, while the integrin is not expressed under normal culture conditions. To confirm the clinical relevance of the integrin expression, the integrin expression was analyzed in heart tissues from infarction patients. Integrin was highly expressed in the infarction region and was almost undetectable in the normal non-infraction region. Integrin a v b3 was upregulated in cardiomyocytes under hypoxia and oxidative stress conditions.
- Extracellular PKM2 (EcPKM2) interacts to integrin avP3 found on angiogenic endothelial cells and myofibroblasts, safeguarding them from apoptosis.
- rPKMl recombinant PKM1
- G415R shoed enhanced solubility- and prolonged stability compared to the recombinant PKM2.
- FIG. 1A reveals that the recombinant G415R protected H9C2 cells from death (e.g., apoptosis) during hypoxic conditions.
- FIG. IB demonstrates that the G415R mutant promoted cell growth in these conditions.
- FIG. 1C shows that recombinant G415R had analogous effects on primary human cardiomyocytes, specifically protecting them from cell death in hypoxia and oxidative stress scenarios.
- FIGs ID and IE depict the G415R mutant's promotion of cell growth in primary cardiomyocytes under hypoxia and oxidative stress conditions.
- Example 4 The recombinant G415R preserved cardiomyocytes in infarction mouse model
- FIG. 2A shows that administration of G415R dramatically decreased MI mice death at all time points.
- FIG. 2B shows that administration of G415R also decreased heart weight vs body weight both in the MI mice at 30 days after infarction.
- MR imaging analyses of blood flow in the heart showed that G415R treatment improved the blood flow of MI mice and restored blood flow of IR mice almost to the same level of the sham mice.
- FIGs, 3 A and 3B display histological analyses of the infarcted heart, revealing that mice treated with G415R had reduced infarction scar sizes compared to the rPKMl and vehicle- treated groups in both MI and IR mice.
- TUNEL staining was conducted on tissues from mice hearts at 6, 24, and 168 hours post-infarction. G415R treatments notably decreased cardiomyocyte apoptosis at 6 and 24 hours, as depicted in FIG. 3C. By 168 hours post-infarction, cardiomyocyte apoptosis was barely detected using TUNEL staining, with no significant variations observed among the various treatment groups, as shown in FIG. 3D.
- G415R was found to stimulate human primary cardiomyocyte proliferation under hypoxia and oxidative stress conditions. Thus, the inventors investigated if G415R also enhanced cardiomyocyte proliferation using Ki67 staining. As anticipated, G415R treatment did not trigger cardiomyocyte proliferation 6 hours post-infarction. Nevertheless, in the G415R-treated mice, evident cardiomyocyte proliferation was observed in myocardium tissues of both MI and IR mice on days 4 and 7 post-infarction (Fig. 3E). The effects of G415R on cardiomyocyte proliferation diminished from day 4 to day 7 and were virtually absent by day 28 post-infarction in both MI and IR mice. This suggests that the optimal period for promoting cardiomyocyte proliferation/regeneration lies between 1 to 7 days post-infarction.
- cTnl cardiac troponin I
- FIG. 4A shows WGA staining of myocardium tissue revealing that G415R treated mice resulted in less infarction scars in infarction myocardium region in both MI and IR models compared to rPKMl and ventical treated group.
- FIGs. 4B and 4C display Masson-Tri chrome staining of myocardium tissue.
- the staining reveals that mice treated with G415R exhibited reduced collagen accumulation in the infarcted myocardium region for both MI and IR models compared to those treated with rPKMl and the vehicle group.
- WGA wheat germ agglutinin
- FIG. 4D and 4E present analyses of the cardiomyocyte cross-section area, using WGA and cTnl co-staining.
- the data indicate that G415R treatment diminished the cardiomyocyte cross-section area nearly to the same extent as seen in the sham groups for both MI models.
- FIGs. 4E and 4F depict results for IR models, highlighting that G415R treatment in infarcted mice significantly curtailed cardiomyocyte hypertrophy.
- a potential explanation for the decreased accumulation of ECM/collagen fibers in the myocardium of G415R-treated mice is that the G415R treatment may have caused fewer cardiac fibroblasts to activate in the MI and IR mice due to the preservation of cardiomyocytes
- FIGs. 4F and 4G showcase the activation of cardiac fibroblasts in the infarcted myocardium of MI and IR mice, as evidenced by IHC staining of a-SMA — a molecular marker for myofibroblasts.
- a-SMA a molecular marker for myofibroblasts.
- PKM2 was expressed in the infarcted heart tissues after 4 days, while no PKM2 staining was detected in normal healthy cardiac tissue. Extracellular PKM2 was seen in the staining of the patient myocardial infarction tissues, the inventors also performed IHC staining of PKM2 in the tissue of mouse infarction heart after different time points of induction of infarction. No PKM2 staining was observed at 6 hours, 24 hours, and 3 days after infarction induction. PKM2 staining was detected in the infarction region 4 days after infarction induction. EcPKM2 was visible in the IHC staining. PKM2 was not detected in plasma of sham mice and the mice at 6 and 24 hours post myocardial infarction.
- PKM2 was detected in plasma of mice 7d after myocardial infarction (not shown).
- the experiments from our and other laboratories suggest that PKM2 is expressed and released into the extracellular space at a late time point of myocardial infarction induction ( ⁇ 4 days post infarction) from, e.g., dead cells.
- FIGs 5A-5D Co-immunoprecipitation experiments were performed using G415R and extracts from primary human cardiomyocyte cells exposed to hypoxic conditions. As shown in FIGs 5A-5D, G415R effectively reduced PTEN expression in cultured cardiomyocy te cells (evidenced by immunoblotting) as well as in myocardium tissue (observed through IHC staining) from mice with infarctions. Interestingly, FIGs 5A-5D illustrate that G415R has an affinity with integrin P3, as evidenced by its co-precipitation, confirmed using antibodies specific for either PKM2 or integrin [33.
- EcPKM2 should the cardioprotective and proliferative effects of EcPKM2 be primarily through PI3K activation, they'd be rendered ineffective by a PI3K inhibitor. Supporting this notion, G415R's influence on H9C2 proliferation was nullified by commercially available FAK and PI3K inhibitors. EcPKM2 fosters a beneficial interaction with integrin avP3. This interaction, in turn, triggers integrin signaling in cardiomyocytes during periods of hypoxic and oxidative stress, providing a shield against apoptosis and promoting cellular proliferation.
Abstract
Procédés de traitement de patients qui ont subi un infarctus du myocarde, également connus sous le nom d'infarctus aigu du myocarde, et de traitement ou d'atténuation des effets de l'infarctus. Ce traitement peut comprendre l'administration d'une composition contenant une protéine qui est sensiblement similaire ou identique à la pyruvate kinase M2 (PKM2) pendant la phase aiguë ou initiale de l'infarctus du myocarde.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263416428P | 2022-10-14 | 2022-10-14 | |
US63/416,428 | 2022-10-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024081960A2 true WO2024081960A2 (fr) | 2024-04-18 |
Family
ID=90670173
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/077001 WO2024081960A2 (fr) | 2022-10-14 | 2023-10-16 | Procédés de conservation et de protection de cardiomyocytes et de réduction de la fibrose cardiaque à la suite d'une lésion cardiaque |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024081960A2 (fr) |
-
2023
- 2023-10-16 WO PCT/US2023/077001 patent/WO2024081960A2/fr unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200325200A1 (en) | Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) | |
US20060025343A1 (en) | Angiogenically effective unit dose fo FGF and method of adminstering | |
US6232288B1 (en) | Composition for improving pancreatic function | |
WO2001068125A2 (fr) | Methodes et compositions de traitement et de prevention de la dyserection | |
US9060977B2 (en) | Heparin binding epidermal growth factor (HB-EGF) for use in methods of treating and preventing intestinal injury related to hemorrhagic shock and resuscitation | |
US20030228283A1 (en) | Preventing secondary lymphedema with VEGF-D DNA | |
US20200368329A1 (en) | System and methods to promote cellular regeneration following ischemia | |
WO2024081960A2 (fr) | Procédés de conservation et de protection de cardiomyocytes et de réduction de la fibrose cardiaque à la suite d'une lésion cardiaque | |
AU2016203988B2 (en) | Protein to promote blood vessel growth and uses thereof | |
CN107050429B (zh) | 人成纤维生长因子21在制备用于治疗脑卒中药物中的应用 | |
US20180221446A1 (en) | Angiogenically Effective Unit Dose Of FGF And Method Of Administering | |
KR20070001995A (ko) | 세포외 매트릭스 축적의 치료 또는 예방법 | |
WO2013009943A2 (fr) | Polypeptides de la micro-utrophine et procédés s'y rapportant |